School-Based H. pylori Screening in Japanese Adolescents: Challenges and Opportunities in Urban Settings

What Does This Initiative Reveal About H. pylori Prevalence in Urban Adolescents?

The recent implementation of a comprehensive Helicobacter pylori screening and eradication program among junior high school students in Yokosuka City, Japan, has yielded significant insights into the prevalence and management of this infection in urban adolescent populations. This three-year initiative, conducted between 2019 and 2021, targeted second-year junior high school students as part of a strategic approach to reduce future gastric cancer risk in a country with traditionally high gastric cancer incidence. The program utilized Japan's established school health check-up system to screen 6,270 students (63.5% of eligible participants) through a two-tiered approach involving initial urine antibody testing followed by confirmatory urea breath tests for antibody-positive cases. This screening methodology revealed an estimated H. pylori prevalence of just 1.2% among the urban adolescent cohort, substantially lower than rates reported in similar studies from other Japanese regions, particularly rural areas where prevalence has typically ranged from 2.6% to 4.8%. The urban setting of Yokosuka City, with its improved water infrastructure and sanitary conditions, likely contributed to this relatively low infection rate, which aligns with broader trends of declining H. pylori prevalence among Japanese youth over recent decades.

How Effective Are the H. pylori Treatment Regimens?

The eradication outcomes from this program highlight significant challenges in treating H. pylori infection in adolescents. All 73 students with confirmed infection received first-line triple therapy consisting of amoxicillin, clarithromycin, and esomeprazole (PAC regimen) for one week. However, the success rate of this first-line treatment was notably low at 50.7% in intention-to-treat analysis and 52.9% in per-protocol analysis. These rates fall below those reported in similar youth programs elsewhere in Japan, raising concerns about the efficacy of standard PAC therapy in this population. The second-line regimen, which replaced clarithromycin with metronidazole (PAM regimen), achieved better results with success rates of 70.8% (ITT) and 85.0% (PP). When combining both treatment lines, the overall eradication success reached 74.0% (ITT) and 94.7% (PP). The marked difference between first and second-line efficacy suggests increasing clarithromycin resistance among H. pylori strains affecting Japanese adolescents, a trend observed nationwide with resistance rates in pediatric populations reportedly increasing from 34.7% to over 40% in recent decades. This finding underscores the urgent need to reconsider first-line treatment options for adolescent H. pylori infection in regions with high clarithromycin resistance prevalence.

Are the Treatments Safe? Understanding Adverse Effects in Adolescents

Adverse events associated with eradication therapy were observed in 27% of students receiving first-line treatment, with gastrointestinal symptoms predominating. Diarrhea was the most common side effect (16.4%), typically occurring within the first three days of treatment and generally resolving within a week. Abdominal pain affected 11% of treated students, while allergic reactions occurred in 5.5% of cases. One student discontinued treatment due to an allergic reaction, but no severe adverse events requiring hospitalization were reported. The side effect profile for second-line therapy was similar, with 22% of students reporting adverse events, primarily diarrhea. These findings are generally consistent with previous studies of H. pylori eradication in adolescents, though the frequency of side effects varied across different regional programs in Japan. The relatively high incidence of gastrointestinal disturbances suggests that adjunctive measures, such as probiotic co-administration, might be beneficial in future programs targeting this age group. Despite these side effects, the overall safety profile of eradication therapy in this adolescent population appears acceptable, with most adverse events being mild and self-limiting.

Could Family Transmission Inform Future H. pylori Control Strategies?

A particularly valuable aspect of this study was the investigation of household transmission patterns through surveys of infected students' family members. Among the 68 H. pylori-positive students who provided valid responses, nearly half (48.5%) reported having at least one infected family member residing in the same household. Parental infection was common, with 23.5% of fathers and 26.5% of mothers testing positive for H. pylori. Sibling infection was less frequent at 4.4%, while grandparental infection was reported in 16.2% of cases. Interestingly, 8.8% of infected students reported that none of their family members were infected, suggesting potential exposure sources outside the household. However, the infection status of many family members remained unknown, limiting the comprehensive assessment of household transmission dynamics. These findings align with previous research demonstrating the significance of parent-to-child transmission in H. pylori epidemiology, with studies from China showing substantially higher infection rates in children with infected parents (34.3%) compared to those with uninfected parents (13.6%). The familial clustering observed in this study suggests that expanding screening and treatment to household members of infected adolescents could enhance the effectiveness of H. pylori control strategies by reducing the risk of reinfection and preventing intergenerational transmission.

What Operational Challenges Impact Program Success?

Program implementation revealed several operational challenges that merit consideration in future adolescent-targeted H. pylori initiatives. The participation rate of 63.5%, while substantial, was lower than rates achieved in some comparable Japanese programs, particularly those that fully integrated H. pylori testing into mandatory school health examinations. For instance, a program in Akita Prefecture reported 97.3% participation by utilizing urine samples already collected for routine health screenings, thereby minimizing additional burden on students. Furthermore, significant attrition occurred throughout the program's clinical pathway: 13% of antibody-positive students did not complete confirmatory testing, 4.1% did not undergo post-treatment assessment following first-line therapy, and 16.7% did not complete evaluation after second-line treatment. These dropout rates highlight the challenges in maintaining adolescent engagement in multi-step clinical protocols, particularly for an infection that is typically asymptomatic. Parental understanding of the long-term cancer prevention benefits of H. pylori eradication may also have influenced participation, as surveys have found that many parents consider such testing unnecessary for their children. These findings parallel challenges observed in other adolescent cancer prevention programs, such as HPV vaccination, where limited awareness of future cancer risk can impede uptake of preventive interventions.

Are Current Treatment Guidelines Adequate for Adolescents?

The modest first-line eradication rate observed in this study raises important questions about optimal treatment strategies for adolescent H. pylori infection in Japan. Current regulatory restrictions significantly limit therapeutic options for this age group, as metronidazole is not approved for use in children under 16 years in Japan despite its demonstrated efficacy against clarithromycin-resistant strains. Similarly, vonoprazan, a potassium-competitive acid blocker that has shown promising results in adult and limited adolescent studies (86.8% eradication rate in one regional program), lacks regulatory approval for pediatric H. pylori eradication due to insufficient safety data. These regulatory constraints represent a significant barrier to implementing more effective eradication regimens in adolescent populations. From a clinical perspective, both metronidazole and vonoprazan are considered reasonably safe for pediatric use based on available evidence, suggesting that regulatory reconsideration may be warranted. Additionally, treatment adherence likely contributed to the observed eradication outcomes, as studies have shown dramatically different success rates between high-adherence (89.9%) and low-adherence (36.8%) pediatric populations. Future programs should incorporate strategies to monitor and support medication adherence among adolescents.

Can These Findings Shape the Future of Adolescent H. pylori Screening Programs?

This study provides valuable real-world evidence on the feasibility and effectiveness of school-based H. pylori screening and eradication in an urban Japanese setting. The findings indicate that such programs can successfully identify and treat infected adolescents, potentially reducing their lifetime risk of H. pylori-associated diseases, particularly gastric cancer. However, the relatively low prevalence, modest first-line eradication rates, and challenges in program participation suggest that refinements are needed to optimize the impact and cost-effectiveness of such initiatives. Future programs should consider: (1) fully integrating H. pylori testing into existing school health examinations to maximize participation; (2) implementing alternative first-line regimens with higher efficacy against clarithromycin-resistant strains; (3) incorporating family-based screening approaches to address household transmission; (4) enhancing educational components to improve understanding of long-term cancer prevention benefits; and (5) developing strategies to support treatment adherence and reduce program attrition. Could these findings influence the design of adolescent H. pylori screening programs in other urban settings worldwide, particularly in regions with declining yet still concerning infection rates? What regulatory and clinical approaches might best address the challenge of clarithromycin resistance in pediatric H. pylori treatment? How might the integration of family screening enhance the long-term effectiveness of adolescent-targeted H. pylori control strategies?

How Do Declining H. pylori Rates Inform Future Public Health Strategies?

The observed pattern of declining H. pylori prevalence in this urban adolescent population reflects broader epidemiological transitions occurring globally, where improved sanitation, reduced household crowding, and changes in family structure have contributed to decreasing infection rates in younger generations. However, even at low prevalence, H. pylori infection remains a significant public health concern in high gastric cancer incidence regions like Japan. The timing of intervention is critical, as eradication before the development of precancerous lesions such as intestinal metaplasia offers the greatest benefit in reducing gastric cancer risk. The adolescent period represents an important window of opportunity, allowing intervention before most individuals develop advanced gastroduodenal pathology while leveraging existing school-based health systems to reach a broad population. As H. pylori prevalence continues to decline in developed nations, targeted screening approaches focusing on higher-risk populations—including those with family history of infection or gastric cancer—may become increasingly relevant. The experiences and challenges documented in this Yokosuka City program provide valuable insights that can inform the development of evidence-based, age-appropriate H. pylori control strategies in similar settings worldwide.

Summary

The study analyzed a three-year H. pylori screening program among junior high school students in Yokosuka City, Japan, screening 6,270 students with a 1.2% infection rate. First-line treatment showed limited success (50.7% ITT), while second-line therapy achieved better results (70.8% ITT). Adverse effects occurred in 27% of first-line treatment recipients, primarily gastrointestinal symptoms. Family transmission analysis revealed that 48.5% of infected students had at least one infected family member. The program faced operational challenges, including a 63.5% participation rate and significant dropout rates. The findings suggest the need for refined treatment approaches, improved program integration with school health systems, and consideration of family-based screening strategies to enhance effectiveness in urban settings.